{"id":10021,"date":"2025-05-18T17:03:39","date_gmt":"2025-05-18T17:03:39","guid":{"rendered":"https:\/\/scf.incorso.info\/market-access\/"},"modified":"2025-12-03T10:27:23","modified_gmt":"2025-12-03T10:27:23","slug":"market-access","status":"publish","type":"page","link":"https:\/\/www.essecieffe.it\/en\/market-access\/","title":{"rendered":"Market Access"},"content":{"rendered":"
<\/div>
<\/div>

Strategy, Pricing and Negotiation<\/span><\/span><\/h1>
<\/div>
<\/i><\/div><\/a>
<\/div><\/div><\/div><\/div><\/div><\/div><\/section>

While drug development is a long journey, access marks the true starting point: connecting innovation with the patients who need it most<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>

<\/div>

Successful market access combines deep knowledge, strategic expertise, and stakeholder management, all aimed at driving the two forces that shape our work: time-to-market and patients\u2019 needs.<\/p>\n<\/div><\/div><\/div><\/div>

At SCF, we believe that an effective access strategy should start right from the clinical development phase. Our strength lies in a deep understanding of European and Italian pricing and reimbursement landscape, both nationally and regionally, enabling us to define the optimal access pathway, early access approach, and pricing strategy for each product and company, with a particular focus on orphan drugs. The SCF team focuses on establish early dialogue with stakeholders through the management of advisory boards and expert meetings, while fostering constructive and long-lasting relationships with regulatory authorities.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>

\n \n \n \n \n <\/filter>\n <\/defs>\n <\/svg>\n<\/div><\/div>